DEFA14A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 14A

(Rule 14a-101)

INFORMATION REQUIRED IN PROXY STATEMENT

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

 

 

Filed by the Registrant  ☒                            Filed by a party other than the Registrant  ☐

Check the appropriate box:

 

Preliminary Proxy Statement

 

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

Definitive Proxy Statement

 

Definitive Additional Materials

 

Soliciting Material Pursuant to §240.14a-12

Frequency Therapeutics, Inc.

(Name of Registrant as Specified in its Charter)

Not applicable.

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

 

  No fee required.
  Fee paid previously with preliminary materials.
  Fee computed on table in exhibit required by Item 25 (b) per Exchange Act Rules 14a-6 (i) (1) and D-11.

 

 

 


LOGO

 

P.O. BOX 8016, CARY, NC 27512-9903

 

Frequency Therapeutics, Inc.

Important Notice Regarding the Availability

of Proxy Materials

 

Stockholders Meeting to be held on

June 21, 2022

For Stockholders of record as of April 22, 2022

 

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting.

 

To view the proxy materials, and to obtain directions to attend the meeting, go to: www.proxydocs.com/FREQ

 

To vote your proxy while visiting this site, you will need the 12 digit control number in the box below.

 

Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet.

 

LOGO

 

LOGO   

For a convenient way to view proxy materials and VOTE go to

www.proxydocs.com/FREQ

 

Have the 12 digit control number located in the shaded box above available

when you access the website and follow the instructions.

 

   LOGO

If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year’s meeting, you must make this request on or before June 10, 2022.

To order paper materials, use one of the following methods.

 

 

LOGO

INTERNET

www.investorelections.com/FREQ

         

 

LOGO

TELEPHONE

(866) 648-8133

         

 

LOGO

* E-MAIL

paper@investorelections.com

When requesting via the Internet or telephone you will need the 12 digit control number located in the shaded box above.

   * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located above) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material.

 

Frequency Therapeutics, Inc.

 

    Meeting Type: Annual Meeting of Stockholders

    Date:

   Tuesday, June 21, 2022

    Time:

   9:00 AM, Eastern Time

    Place:

   Annual Meeting to be held live via the Internet - please visit
   www.proxydocs.com/FREQ for more details.

TO ATTEND the Annual Meeting of Frequency Therapeutics, Inc., please visit www.proxydocs.com/FREQ for virtual meeting registration details.

 

SEE REVERSE FOR FULL AGENDA


Frequency Therapeutics, Inc.

Annual Meeting of Stockholders

THE BOARD OF DIRECTORS RECOMMENDS A VOTE:

FOR ON PROPOSALS 1 AND 2

 

PROPOSAL

 

1.

To elect two (2) class III directors, each to serve until the 2025 annual meeting of our stockholders.

1.01 Timothy J. Barberich

1.02 Robert S. Langer

 

2.

To ratify, in a non-binding vote, the appointment of RSM US LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022.

NOTE: To transact such other business as may properly come before the Annual Meeting or any continuation, postponement or adjournment thereof.